Weekly Research Analysts’ Ratings Updates for ANI Pharmaceuticals (ANIP)

ANI Pharmaceuticals (NASDAQ: ANIP) recently received a number of ratings updates from brokerages and research firms:

• 3/17/2025 – ANI Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $94.00 price target on the stock.
• 3/14/2025 – ANI Pharmaceuticals was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 3/14/2025 – ANI Pharmaceuticals is now covered by analysts at Jefferies Financial Group Inc.. They set a “buy” rating and a $80.00 price target on the stock.
• 3/12/2025 – ANI Pharmaceuticals is now covered by analysts at JPMorgan Chase & Co.. They set an “overweight” rating and a $85.00 price target on the stock.
• 3/5/2025 – ANI Pharmaceuticals had its price target raised by analysts at Guggenheim from $84.00 to $86.00. They now have a “buy” rating on the stock.
• 3/3/2025 – ANI Pharmaceuticals was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 3/3/2025 – ANI Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $94.00 price target on the stock.
• 2/5/2025 – ANI Pharmaceuticals was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 1/28/2025 – ANI Pharmaceuticals was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.

ANI Pharmaceuticals Stock Down 0.8 %

Shares of NASDAQ ANIP traded down $0.52 during trading hours on Thursday, hitting $64.35. The stock had a trading volume of 200,568 shares, compared to its average volume of 239,003. The company has a market capitalization of $1.40 billion, a P/E ratio of -117.00 and a beta of 0.63. The firm’s 50-day moving average price is $59.00 and its two-hundred day moving average price is $58.12. ANI Pharmaceuticals, Inc. has a 52 week low of $52.50 and a 52 week high of $70.81. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74.

Insider Activity

In related news, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total value of $25,332.00. Following the transaction, the vice president now owns 80,545 shares in the company, valued at $5,100,914.85. This trade represents a 0.49 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction on Friday, March 7th. The stock was sold at an average price of $60.86, for a total transaction of $60,860.00. Following the completion of the transaction, the senior vice president now owns 66,525 shares in the company, valued at $4,048,711.50. This trade represents a 1.48 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 3,200 shares of company stock valued at $191,776 over the last 90 days. 12.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ANIP. US Bancorp DE increased its holdings in shares of ANI Pharmaceuticals by 842.9% during the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock worth $33,000 after purchasing an additional 531 shares during the period. KBC Group NV increased its holdings in shares of ANI Pharmaceuticals by 89.2% during the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock worth $70,000 after purchasing an additional 600 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in shares of ANI Pharmaceuticals during the 4th quarter valued at about $166,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of ANI Pharmaceuticals by 24.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after acquiring an additional 579 shares in the last quarter. Finally, Rafferty Asset Management LLC acquired a new stake in shares of ANI Pharmaceuticals during the 4th quarter valued at about $200,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.